ArticleGynecologic oncology reports2026
Variations and patterns in germline and somatic testing by age in ovarian, primary peritoneal, and fallopian tube cancer patients: a descriptive analysis in a large, real-world clinical and genetic data registry.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the relationship between genomic instability score and age distribution in ovarian, primary peritoneal, and fallopian tube cancers and to characterize age-related patterns in germline, homologous recombination deficiency (HRD), and somatic tumor testing using a large real-world clinical registry. Methods: Patients with ovarian, primary peritoneal, and fallopian tube cancers who underwent germline and/or somatic testing were identified from the Myriad Collaborative Research Registry (MCRR), version 4 (March 2025). Genomic instability scores (GIS) and tumor mutation profiles were analyzed across four age groups (<50, 50-59, 60-69, and ≥70 years). HRD positivity was defined as GIS ≥ 42. Testing patterns were evaluated by ordering specialty. Comparisons were performed using chi-square testing with significance defined as p < 0.05. Results: Among 110,119 patients with ovarian, peritoneal, or fallopian tube cancer, HRD positivity decreased with increasing age (36.2% in <50 years, 36.4% in 50-59 years, 30.9% in 60-69 years, and 24.2% in ≥70 years; p < 0.0001). Median GIS was similar across age groups but demonstrated narrower distribution ranges in older patients. Subgroup analysis of patients with intermediate GIS scores (35-41) showed increasing prevalence with advancing age. Gynecologic oncologists ordered significantly more HRD tests than medical oncologists; however, HRD positivity rates were similar between specialties. Peritoneal cancer diagnoses increased with age. Conclusion: Younger patients demonstrated higher rates of HRD positivity compared to older patients despite similar median GIS distributions. These findings may have implications for biomarker-driven therapeutic selection and clinical trial generalizability, particularly in older ovarian cancer populations. Further investigation is needed to understand age-related molecular differences and optimize testing and treatment strategies across age groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.